American College of Cardiology Meeting In Brief: Merck's Prinivil
Executive Summary
Merck's Prinivil: Retrospective, subgroup analysis of diabetic patients from the GISSI-3 trial shows that treatment with Prinivil (lisinopril) within 24 hours of a suspected myocardial infarction results in a significant decrease in mortality at six weeks for both non-insulin dependent and insulin dependent diabetics, Giulio Zuanetti, Istituto Mario Negri, Milan, reported March 25 at ACC. NIDD patients (n=1,130) receiving lisinopril show a 22% reduction in mortality at six weeks compared to 1,164 NIDD patients receiving placebo, and IDD patients receiving lisinopril (n=254) show a 44.4% reduction in mortality at six weeks compared to 242 IDD patients receiving placebo. Survival rates for both NIDD and IDD patients receiving lisinopril at six weeks was 91% compared to 80% for NIDD and IDD patients on placebo (p=.0005)...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth